Carlos Huauya Leuyacc
Internal Medicine · New York, NYNPI 1487273660
Payments from drug & device makers
Across 81 payments — averaging $26.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$354
- GSK$262
- Novo Nordisk$233
- AbbVie$174
- Xeris Pharmaceuticals, Inc.$147
- Exact Sciences$126
- plus $882 from 17 others
What the payments were for
- Food & beverage$2,179100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 7 | $354 |
| GSK | 13 | $262 |
| Novo Nordisk | 8 | $233 |
| AbbVie | 11 | $174 |
| Xeris Pharmaceuticals, Inc. | 2 | $147 |
| Exact Sciences | 6 | $126 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $114 |
| Bayer | 4 | $96 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $96 |
| Corcept Therapeutics | 1 | $90 |
| Amgen | 4 | $88 |
| Ardelyx, Inc. | 3 | $76 |
| Lundbeck LLC | 3 | $73 |
| Novartis | 3 | $55 |
| Pfizer | 2 | $32 |
| Phathom Pharmaceuticals, Inc. | 1 | $32 |
| Ironwood Pharmaceuticals, Inc | 1 | $25 |
| Daiichi Sankyo Inc. | 1 | $19 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $19 |
| Phadia US Inc. | 1 | $18 |
| Aimmune Therapeutics, Inc. | 1 | $18 |
| Lilly USA, LLC | 1 | $16 |
| Abiomed | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIRSUPRA$127
- GVOKE HYPOPEN$124
- BREZTRI$122
- CAPLYTA$114
- Ozempic$106
How this compares
$2,179 in reported general payments places this provider in the 80th percentile of 9,771 internal medicine providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 47 | $60,425 |
| FarxigaDapagliflozin Propanediol | 24 | $35,413 |
| EliquisApixaban | 33 | $34,023 |
| JanuviaSitagliptin Phosphate | 20 | $30,408 |
| VascepaIcosapent Ethyl | 40 | $24,660 |
| OzempicSemaglutide | 19 | $17,221 |
| JanumetSitagliptin Phos/Metformin Hcl | 14 | $15,467 |
| LinzessLinaclotide | 20 | $10,154 |
| Xigduo XrDapaglifloz Propaned/Metformin | 11 | $8,089 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 20 | $4,832 |
| Atorvastatin Calcium | 209 | $2,311 |
| Novolog FlexpenInsulin Aspart | 13 | $1,180 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 27 | $1,147 |
| Omeprazole | 86 | $784 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 28 | $734 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $354 | $35,41324 claims |
| PfizerEliquis | $32 | $34,02333 claims |
| Novo NordiskOzempic | $233 | $17,22119 claims |
| AbbVieLinzess | $174 | $10,15420 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in New York
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- Sally LauNew York$8.4M
- Maria RubinsteinNew York$6.3M
- Dana RathkopfNew York$6M
- Eytan SteinNew York$5.8M
- James GreenwaldNew York$4.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.